China-based Lynk Pharmaceuticals Co., Ltd has successfully raised RMB 200 million (USD 28.3 million) through a Series C1 financing round. The investment was led by China Grand Prosperity Investment, with participation from Tailong VC and LIANDO. The proceeds from this funding round will be utilized to accelerate the clinical development of Lynk’s core products.
Lynk Pharma’s Focus on Small-Molecule Drugs
Founded in 2018, Lynk Pharmaceuticals is dedicated to the research and development (R&D) of small-molecule drugs targeting oncology and autoimmune diseases. The company has established a robust product pipeline consisting of 10 drugs, with four indications at Phase II stages. This demonstrates Lynk Pharma’s commitment to advancing innovative therapies for significant unmet medical needs.
Leading Pipeline Candidate: LNK01001
The pipeline is headlined by LNK01001, a JAK1 inhibitor under development for autoimmune diseases. This drug candidate represents the company’s strategic focus on precision medicine and its potential to improve patient outcomes in the treatment of autoimmune conditions.-Fineline Info & Tech
